3rd Quarter - Amendment

SANOFI US SERVICES INC. for SANOFI US SERVICES INC

Firm
Client
Income
—
Expenses
$1,030,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 15, 2012 $710,000 Replaced
3rd Quarter - Amendment (this page) Jun 14, 2013 $1,030,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" and S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)"; and efforts to add Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
EDWARD GREISSING —
PATRICK MAYES MCLAIN —
ANN TAYLOR —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 942 (112th)

Economics/Economic Development ECN

General issues related to foreign direct investment in the United States, including all provisions of S3274 and HR5910 "Global Investment in American Jobs Act of 2012"

Foreign entity interest: Sanofi SA, the foreign parent corporation of sanofi-aventis U.S. Inc., as disclosed on its LD-1

LobbyistCovered position, as disclosed
EDWARD GREISSING —
PATRICK MAYES MCLAIN —
ANN TAYLOR —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5910 (112th)

Health Issues HCR

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues relatedto diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
TIMOTHY CLARK —
MARYANNE DOLBEARE DUNLAP —
EDWARD GREISSING —
PATRICK MAYES MCLAIN —
AMY L REDL —
ANN TAYLOR —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 436 (112th), H.R. 4223 (112th), H.R. 3627 (112th), H.Res. 295 (112th), H.R. 2405 (112th), H.R. 2529 (112th)

Medicare/Medicaid MMM

Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
TIMOTHY CLARK —
EDWARD GREISSING —
PATRICK MAYES MCLAIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Animals ANI

S3239 and HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; and issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics

Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
MARYANNE DOLBEARE DUNLAP —
EDWARD GREISSING —
PATRICK MAYES MCLAIN —
AMY L REDL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3798 (112th)

Affiliated organisations

OrganisationLocation
GENZYME CORPORATION Cambridge, MA, US
SANOFI PASTEUR INC. Swiftwater, PA, US

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.